Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies

British Journal of Haematology

Volumn 169, Issue 1, 2015, Pages 90-102

  Schuster, Friedhelm R ^a   Stanglmaier, Michael ^b   Woessmann, Wilhelm ^c   Winkler, Beate ^d   Siepermann, Meinolf ^a   Meisel, Roland ^a   Schlegel, Paul G ^d   Hess, Jürgen ^e   Lindhofer, Horst ^b,e   Borkhardt, Arndt ^a   Buhmann, Raymund ^f,g  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b TRION Research GmbH   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e TRION Pharma GmbH   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Anti CD20 x anti CD3; B cell malignancies; Bispecific antibody; Children; Immunotherapy

Indexed keywords

CD20 ANTIBODY; CD3 ANTIBODY; CLEMASTINE; DASATINIB; FBTA05; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LENALIDOMIDE; MERCAPTOPURINE; NILOTINIB; PARACETAMOL; RANITIDINE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BI20 ANTIBODY; BISPECIFIC ANTIBODY;

ADOLESCENT; ALLERGIC REACTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER PROGNOSIS; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; LIVER DISEASE; LONG TERM CARE; MALE; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PEDIATRICS; PRIORITY JOURNAL; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ALLOGRAFTS; ANTIBODIES, BISPECIFIC; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84925114367     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13242     Document Type: Article

References (37)

1. Anoop, P., Sankpal, S., Stiller, C., Tewari, S., Lancaster, D.L., Khabra, K. & Taj, M.M. (2012) Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leukemia & Lymphoma, 53, 1882-1888.
2. Atanackovic, D., Reinhard, H., Meyer, S., Spock, S., Grob, T., Luetkens, T., Yousef, S., Cao, Y., Hildebrandt, Y., Templin, J., Bartels, K., Lajmi, N., Stoiber, H., Kroger, N., Atz, J., Seimetz, D., Izbicki, J.R. & Bokemeyer, C. (2013) The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines & Immunotherapeutics, 9, 2533-2542.
3. Atra, A., Gerrard, M., Hobson, R., Imeson, J.D., Hann, I.M. & Pinkerton, C.R. (2001) Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. British Journal of Haematology, 112, 965-968.
4. Attarbaschi, A., Dworzak, M., Steiner, M., Urban, C., Fink, F.M., Reiter, A., Gadner, H. & Mann, G. (2005) Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatric Blood & Cancer, 44, 70-76.
5. Buhmann, R., Simoes, B., Stanglmaier, M., Yang, T., Faltin, M., Bund, D., Lindhofer, H. & Kolb, H.J. (2009) Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplantation, 43, 383-397.
6. Buhmann, R., Stanglmaier, M., Hess, J., Lindhofer, H., Peschel, C. & Kolb, H.J. (2013) Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. Journal of Translational Medicine, 11, 160-168.
7. Burkhardt, B., Reiter, A., Landmann, E., Lang, P., Lassay, L., Dickerhoff, R., Lakomek, M., Henze, G. & von Stackelberg, A. (2009) Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. Journal of Clinical Oncology, 27, 3363-3369.
8. Cairo, M.S., Gerrard, M., Sposto, R., Auperin, A., Pinkerton, C.R., Michon, J., Weston, C., Perkins, S.L., Raphael, M., McCarthy, K., Patte, C. & on behalf of the FAB LMB96 International Study Committee. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood, 109, 2736-2743.
9. Chames, P. & Baty, D. (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs, 1, 539-547.
10. Dworzak, M.N., Schumich, A., Printz, D., Potschger, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G. & Gadner, H. (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 112, 3982-3988.
11. Eissler, N., Ruf, P., Mysliwietz, J., Lindhofer, H. & Mocikat, R. (2012) Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Research, 72, 3958-3966.
12. Eissler, N., Mysliwietz, J., Deppisch, N., Ruf, P., Lindhofer, H. & Mocikat, R. (2013) Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy. Molecular Medicine, 19, 54-61.
13. Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Briere, J., Moskowitz, C.H. & Schmitz, N. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 4184-4190.
14. Griffin, T.C., Weitzman, S., Weinstein, H., Chang, M., Cairo, M., Hutchison, R., Shiramizu, B., Wiley, J., Woods, D., Barnich, M., Gross, T.G. & Children's Oncology, G. (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20 + ) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 52, 177-181.
15. Harjunpaa, A., Wiklund, T., Collan, J., Janes, R., Rosenberg, J., Lee, D., Grillo-Lopez, A. & Meri, S. (2001) Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leukemia & Lymphoma, 42, 731-738.
16. Heiss, M.M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O.O., Ivanchenko, V.V., Dudnichenko, A.S., Aleknaviciene, B., Razbadauskas, A., Gore, M., Ganea-Motan, E., Ciuleanu, T., Wimberger, P., Schmittel, A., Schmalfeldt, B., Burges, A., Bokemeyer, C., Lindhofer, H., Lahr, A. & Parsons, S.L. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer, 127, 2209-2221.
17. Hess, J., Ruf, P. & Lindhofer, H. (2012) Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncology, 8, 73-85.
18. Kiewe, P., Hasmuller, S., Kahlert, S., Heinrigs, M., Rack, B., Marme, A., Korfel, A., Jager, M., Lindhofer, H., Sommer, H., Thiel, E. & Untch, M. (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clinical Cancer Research, 12, 3085-3091.
19. Kobrinsky, N.L., Sposto, R., Shah, N.R., Anderson, J.R., DeLaat, C., Morse, M., Warkentin, P., Gilchrist, G.S., Cohen, M.D., Shina, D. & Meadows, A.T. (2001) Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: children's Cancer Group Study CCG-5912. Journal of Clinical Oncology, 19, 2390-2396.
20. Kufer, P., Lutterbuse, R. & Baeuerle, P.A. (2004) A revival of bispecific antibodies. Trends in Biotechnology, 22, 238-244.
21. Maher, J. & Adami, A.A. (2013) Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Research, 73, 5613-5617.
22. Meinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schaub, G., Klein, C., Kabickova, E., Klapper, W., Attarbaschi, A., Schrappe, M. & Reiter, A. & Berlin-Frankfurt-Munster, g. (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of Clinical Oncology, 28, 3115-3121.
23. Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y. & Slavin, S. (2006) Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood, 107, 1564-1569.
24. Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Ruf, P. & Slavin, S. (2008) Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Expermimental Hematology, 36, 997-1003.
25. Nagorsen, D. & Baeuerle, P.A. (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Experimental Cell Research, 317, 1255-1260.
26. Ott, M.G., Marme, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M.M., Linke, R. & Seimetz, D. (2012) Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. International Journal of Cancer, 130, 2195-2203.
27. Patte, C., Auperin, A., Gerrard, M., Michon, J., Pinkerton, R., Sposto, R., Weston, C., Raphael, M., Perkins, S.L., McCarthy, K. & Cairo, M.S. (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood, 109, 2773-2780.
28. Pietzner, K., Vergote, I., Santoro, A., Chekerov, R., Marme, F., Rosenberg, P., Martinius, H., Friccius-Quecke, H. & Sehouli, J. (2014) Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study. Medical Oncology, 31, 308.
29. Poirel, H.A., Cairo, M.S., Heerema, N.A., Swansbury, J., Auperin, A., Launay, E., Sanger, W.G., Talley, P., Perkins, S.L., Raphael, M., McCarthy, K., Sposto, R., Gerrard, M., Bernheim, A. & Patte, C. (2009) Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia, 23, 323-331.
30. Rubenstein, J.L., Combs, D., Rosenberg, J., Levy, A., McDermott, M., Damon, L., Ignoffo, R., Aldape, K., Shen, A., Lee, D., Grillo-Lopez, A. & Shuman, M.A. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 101, 466-468.
31. Ruf, P. & Lindhofer, H. (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood, 98, 2526-2534.
32. Stanglmaier, M., Faltin, M., Ruf, P., Bodenhausen, A., Schroder, P. & Lindhofer, H. (2008) Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. International Journal of Cancer, 123, 1181-1189.
33. Ward, E., Desantis, C., Robbins, A., Kohler, B. & Jemal, A. (2014) Childhood and adolescent cancer statistics, 2014. CA - A Cancer Journal for Clinicians, 64, 83-103.
34. Woessmann, W.. (2013) XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma? Hematological Oncology, 31(Suppl 1), 64-68.
35. Woessmann, W., Seidemann, K., Mann, G., Zimmermann, M., Burkhardt, B., Oschlies, I., Ludwig, W.D., Klingebiel, T., Graf, N., Gruhn, B., Juergens, H., Niggli, F., Parwaresch, R., Gadner, H., Riehm, H., Schrappe, M. & Reiter, A. & Group, B.F.M. (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood, 105, 948-958.
36. Zeidler, R., Reisbach, G., Wollenberg, B., Lang, S., Chaubal, S., Schmitt, B. & Lindhofer, H. (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. The Journal of Immunology, 163, 1246-1252.
37. Zeidler, R., Mysliwietz, J., Csanady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B. & Lindhofer, H. (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. British Journal of Cancer, 83, 261-266.